Indian Pharmaceutical Alliance Urges U.S.-India Partnership for Affordable Medicine Resilience

The Indian Pharmaceutical Alliance (IPA), representing 23 leading Indian research-based generic pharmaceutical companies, convened today at the DAR Museum in Washington DC. The focus of the gathering was to advocate for a strategic trade partnership between the United States and India to bolster the pharmaceutical supply chain and ensure affordable medicine resilience for both nations. The agenda was enhancing health security and reducing reliance on foreign sources for pharmaceuticals.

Central to the IPA’s call for action was a seminal study released by the IQVIA Institute for Human Data Science, titled “U.S.-India Medicine Partnership: India’s Contributions to U.S. Healthcare.” This comprehensive report underscores India’s pivotal role in the U.S. healthcare system, emphasizing the symbiotic relationship between the two countries in strengthening health security and ensuring access to essential medicines.

The executives from IPA highlighted the urgency of forging a transformative “Affordable Medicine Partnership” to address the vulnerabilities exposed by the COVID-19 pandemic and other global health crises. Sharvil Patel, Vice President of IPA and Managing Director of Zydus Lifesciences, emphasized the need to restore balance and resilience in pharmaceutical supply chains, stressing that this is not just prudent but crucial for both nations’ health security.

The proposed Affordable Medicine Partnership aligns closely with President Biden’s Executive Order on America’s supply chains, which identified pharmaceuticals and active pharmaceutical ingredients (APIs) as critical supply chain risks. Patel reiterated the imperative of building resilient, diverse, and secure supply chains to safeguard economic prosperity and national security.

According to the IQVIA Institute report, Indian pharmaceutical companies play a pivotal role in providing affordable medicines to Americans, with 90 percent of all prescribed medicines being generic and nearly half of those prescriptions filled with products manufactured by Indian firms. The annual savings to the U.S. healthcare system from these companies exceed $219 billion, underscoring their indispensable contribution to healthcare affordability and accessibility.

Vinita Gupta, CEO of Lupin, emphasized the strategic significance of the proposed partnership, framing it as a foundational step towards strengthening health infrastructure vital to mutual prosperity and security. Gupta highlighted the initiative’s alignment with existing U.S.-India collaborations in energy, climate, and semiconductors, emphasizing the interconnection between health, industrial prowess, and national security.

The IPA delegation is currently engaged in high-level meetings with the Administration and members of Congress to advocate for the establishment of an “Affordable Medicine Trade Partnership,” akin to efforts aimed at reducing reliance on semiconductor chips and other critical national security needs. As stewards of this transformative partnership, the IPA remains steadfast in its commitment to building a resilient global health infrastructure that supports economic stability and security worldwide.

Leave a Reply

Your email address will not be published. Required fields are marked *